Lifeline Biotechnologies Inc (LLBO)

[Domains]

World Precision Medicine Congress (17-19 May 2017)

Cyrcadia is a wearable device company which utilizes predictive analytic modeling for early breast cancer detection. Feel free to view Cyrcadia’s Introductory Message. After completion of historic clinical trials with over 200 patients and seven years of predictive algorithmic research, three patents were issued in 2012.

We are now in our final US validation trial at El Camino Hospital in Mt. View, CA and The Ohio State University. The targeted outcome for this 173 patient trial is to prove our technology can be a valuable adjunctive screening approach and improve on dense tissue diagnostic accuracy. Currently 28 states regulate that the physician must inform the patient about her condition of density, that she has a higher propensity for cancer, and that the current diagnostic modalities are challenged by her condition. Breast density affects 40% of the female population globally, and today no solid screening solution exists. See Are You Dense Foundation.

A secondary outcome of the trial is to prove Cyrcadia's value as an adjunctive screening tool to help reduce the current 70%+ level of biopsies occurring on non-cancerous breast tissue through mammography interpretation, or 1.2M biopsies on non-cancerous tissue, annually.

The trials and associated algorithms are hitting the target of 80% Specificity and 77% overall accuracy demonstrating that when used as an adjunctive screening solution, Cyrcadia could substantially reduce the current 1.2M biopsies in the US being conducted on non-cancerous tissue. Additionally, 83% of the current enrollees into this trial have dense parenchymal tissue which increases our confidence of Cyrcadia’s tissue agnostic value for screening the dense tissue population globally. A technology roadmap exists beyond breast cancer for the wearable market, but we are first proving ourselves in this much needed market.

We are honored to say that Stanford University in Palo Alto, CA have asked us to lead a global randomized trial/pilot program for Stanford's Medicine X and Evidation Health programs. The founder of the Medicine X program, Dr. Larry Chu is tied to President Obama's Precision Medicine Initiative. Dr. Chu states that Cyrcadia is an example of what Stanford sees as an exact fit of technology with this "Everyone Included" healthcare initiative. Brigham and Woman’s, Ochsner Clinic, Dignity Health have expressed interest in participation with the Med X pilot. Through Medicine X we are committed to expand this pilot trial to India, Japan, S. Korea, Australia and Italy which will infuse our 2017 global launch.

Cyrcadia has achieved two nationally ranked awards in 2016. Cyrcadia won the Gold Edison Award for the Top Healthcare Wearable Technology for 2016, and as one of the Top 40 Healthcare Transformers for 2016, both through selection from thousands of participants in these categories.

Feel free to visit Cisco's site about Cyrcadia called Detected and visit Detected Movie Trailer which is the precursor to the actual documentary release due out late 2016 or early 2017 about our technological launch. Cisco's representatives stated they perceive our technology as a significant catalyst to improving healthcare delivery globally through wearable devices and they would like to track our progress in shifting the wearable market from simple fitness devices to personalized healthcare monitoring leading to earlier cancer diagnosis and associated intervention.

Rob Royea, Chief Executive Officer, Cyrcadia Health Inc.

www.terrapinn.com/conference/world-precision-medicine-congress/Free-NHS-track.stm